This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AKN-083

Allergan plc

Drug Names(s): FXR Agonist Program (Akarna), AKN083, AKN 083

Description: FXR is a nuclear hormone receptor expressed in the liver, intestine, kidney and fat (adipose) tissue. Akarna is developing a small molecule, non-bile acid FXR agonist that has high affinity, potency and selectivity for FXR.

Deal Structure: Allergan and Akarna
In September 2016, Allergan announced that the Company has acquired Akarna Therapeutics for an up-front payment of $50 million, subject to certain adjustments, as well as potential clinical, regulatory and commercial milestone payments related to its lead development compound, AKN-083. In addition to AKN-083, the acquisition also includes a portfolio of additional development-stage FXR compounds.


AKN-083 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug